Apoptotic response through a high mobility box 1 protein-dependent mechanism in LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Kuroda, Noriyuki ^a   Inoue, Kouji ^a   Ikeda, Tadayuki ^a   Hara, Yaiko ^a   Wake, Kenjiro ^a,b   Sato, Tetsuji ^a  

^a TSURUMI UNIVERSITY   (Japan)

^b Minophagen Pharmaceutical Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GALACTOSAMINE; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; LYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, MOUSE; CARRIER PROTEIN; GLUTATHIONE TRANSFERASE; GSTO1 PROTEIN, MOUSE; HISTONE DEACETYLASE; MESSENGER RNA; PROTEIN BINDING; TOLL LIKE RECEPTOR 4;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; EXPERIMENTAL HEPATITIS; GENE EXPRESSION; GSTO1 GENE; IMMUNOREACTIVITY; INFLAMMATORY INFILTRATE; LIVER CELL; LIVER INJURY; LIVER PROTECTION; MALE; MICROARRAY ANALYSIS; MOUSE; NICK END LABELING; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; ACETYLATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED; DENDRITIC CELL; DRUG EFFECTS; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; GENETICS; KUPFFER CELL; LIVER FAILURE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; TIME;

ACETYLATION; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; CARRIER PROTEINS; DENDRITIC CELLS; EXTRACELLULAR SPACE; GALACTOSAMINE; GENE EXPRESSION REGULATION; GLUTATHIONE TRANSFERASE; GLYCYRRHIZIC ACID; HISTONE DEACETYLASES; HMGB1 PROTEIN; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER FAILURE; MALE; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN TRANSPORT; RNA, MESSENGER; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

EID: 84898891676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092884     Document Type: Article

References (78)

1. Bustin M, Hopkins RB, Isenberg I (1978) Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem 253:1694-1699. (Pubitemid 8312351)
2. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251. (Pubitemid 29329996)
3. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195. (Pubitemid 34773774)
4. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135-1143. (Pubitemid 40524681)
5. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, et al. (2007) HMGB1 release induced by liver ischemia involves Toll-like receptor 4-dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 204:2913-2923. (Pubitemid 350179560)
6. Ilmakunnas M, Tukiainen A, Rauvala H, Arola J, Nordin A, et al. (2008) High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Trans 14:1517-1525.
7. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-570. (Pubitemid 30666257)
8. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, et al. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652-2660. (Pubitemid 36857626)
9. Hori O, Brett J, Slattery T, Cao R, Zhang J, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270:25752-25761.
10. Ivanov S, Dragoi A-M, Wang X, Dallacosta C, Louten J, et al. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970-1981. (Pubitemid 47443911)
11. Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature Immunol 8:487-496. (Pubitemid 46605917)
12. Sha Y, Zmijewski J, Xu Z, Abraham E (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180:2531-2537.
13. Sass G, Heinlein S, Agli A, Bang R, Schumann J, et al. (2002) Cytokine expression in three mouse model of experimental hepatitis. Cytokine 19:115-120. (Pubitemid 35216191)
14. Itokazu Y, Segawa Y, Omata T, Inoue N, Tsuzuike N, et al. (2000) Effects of ZNC-2381, a new oral compound, on several hepatic injury models and on hepatocellular apoptosis in mice and rat. J Pharm Pharmacol 52:531-538. (Pubitemid 30319157)
15. Yoshida T, Abe K, Ikeda T, Matsushita T, Wake K, et al. (2007) Inhibitory effect of glycyrrhizin on lipopolysaccharide and D-galactosamine-induced mouse liver injury. Eur J Pharmacol 576:136-142. (Pubitemid 47593025)
16. Nowak M, Gaines GC, Rosenberg J, Minter R, Bahjat FR, et al. (2000) LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Inter Comp Physiol 278:1202-1209.
17. Ikeda T, Abe K, Kuroda N, Kida Y, Inoue H, et al. (2008) The inhibition of apoptosis by glycyrrhizin in hepatic injury induced by injection of lipopolysaccharide/ D-garactosamine in mice. Arch Histol Cytol 71:163-178.
18. Ohuchi K, Kamada Y, Levine L, Tsurufuji S (1981) Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins Med 7:457-463. (Pubitemid 12249608)
19. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, et al. (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361:2045-2046. (Pubitemid 36695048)
20. Shin YW, Bae EA, Lee SH, Kim JA, Kim YS, et al. (2007) In vitro and in vivo antiallergic effects of glycyrrhiza glabra and its components. Planta Med 73:257-261.
21. Kimura M, Inoue H, Hirabayashi K, Natsume H, Ogihara M (2001) Glycyrrhizin and some analogues induce growth of primary cultured adult rat hepatocytes via epidermal growth factor receptors. Eur J Pharmacol 431:151-161. (Pubitemid 33132121)
22. Okamoto T, Kanda T (1999) Glycyrrhizin protects mice from concanavalin Ainduced hepatitis without affecting cytokine expression. Int J Mol Med 4:149- 152.
23. Okamoto T (2000) The protective effect of glycyrrhizin on anti-Fas antibodyinduced hepatitis in mice. Eur J Pharmacol 387:229-232.
24. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, et al. (1997) The long term efficacy and glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500. (Pubitemid 27154778)
25. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, et al. (2006) A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 51:603-609.
26. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, et al. (1999) Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14:1093-1099.
27. van Rossum TG, Vulto AG, Hop WC, Schalm SW (1999) Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. Clin Ther 21:2080-2090. (Pubitemid 30043923)
28. van Rossum TG, Vulto AG, Hop WC, Schalm SW (2001) Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 96:2432-2437. (Pubitemid 32769207)
29. Manns MP, Wedemeyer H, Singer A, Khomutjanskaja N, Dienes HP, et al. (2012) Glycyrrhizinin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. J Viral Hepat 19:537-546.
30. Mollica L, Marchis FD, Spitaleri A, Dallacosta C, Pennacchini D, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14:431-441. (Pubitemid 46617319)
31. Smolarczyk R, Cichoñ T, Matuszczak S, Mitrus I, Lesiak M, et al. (2012) The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp 60:391-399.
32. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Seara JE (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 312:3526-3538. (Pubitemid 44470773)
33. Youn JH, Shin JS (2006) Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 177:7889-7897.
34. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551-5560. (Pubitemid 37279964)
35. Sato T, Yamamoto H, Sasaki C, Wake K (1998) Maturation of rat dendritic cells during intrahepatic translocation evaluated using monoclonal antibodies and electron microscopy. Cell Tissue Res 294:503-514. (Pubitemid 28510862)
36. Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11:805-815. (Pubitemid 12237981)
37. Naito M, Takahashi K (1991) The role of Kupffer cells in glucan-induced granuloma formation in the liver of mice depleted of blood monocytes by administration of strontium-89. Lab Invest 64:664-674.
38. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, et al. (2010) High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285:39888-39897.
39. van Beijnum JR, Buurman WA, Griffioen AW (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11:91-99.
40. Abe K, Ikeda T, Wake K, Sato T, Sato T, et al. (2008) Glycyrrhizin prevents of lipopolysacchararide/D-galactosamine-induced liver injury through downregulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol 60:91-97.
41. + T lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 100:279-289.
42. Kubes P (1999) The role of adhesion molecules and nitric oxide in intestinal and hepatic ischemia/reperfusion. Hepato-Gastroenterol 46:1458-1463.
43. Liu P, Xu B, Hock CE, Nagele R, Sun FF, et al. (1998) NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am J Physiol 44:H2191-H2198.
44. Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder T, et al. (1999) P-selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology 29:1494-1502.
45. Johns EW (1964) Studies on histone 8. A degradation product of lysine-rich histone. Biochem J 93:161-163.
46. Bustin M (1999) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19:5237-5246.
47. Calogero S, Grassi F, Aguzzi A, Voigtländer T, Ferrier P, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 22:276-280. (Pubitemid 29297255)
48. Wang Y, Liu J, Wu Y, Luo W, Lin SH, et al. (2001) Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res 61:4112-4121.
49. Yang H, Wang H, Czura CJ, Tracey KJ (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1-8. (Pubitemid 40979937)
50. Ito I, Fukazawa J, Yoshida M (2007) Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282:16336-16344. (Pubitemid 47100350)
51. Bell CW, Jiang W, Reich CF 3rd, Pisetsky DS (2006) The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 291:1318-1325.
52. Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, Stenfors J, et al. (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104:1174-1182. (Pubitemid 39038040)
53. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342. (Pubitemid 40516158)
54. Oshima G, Shinoda M, Tanabe M, Ebinuma H, Nishiyama R, et al. (2012) Increased plasma levels of high mobility group box 1 in patients with acute liver failure. Eur Surg Res 48:154-162.
55. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, et al. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573. (Pubitemid 40365558)
56. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955. (Pubitemid 32946067)
57. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, et al. (1999) Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749.
58. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901. (Pubitemid 29375048)
59. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, et al. (2004) Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39:422-432. (Pubitemid 38222183)
60. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, et al. (2002) RAGE and arthritis: the G825 polymorphism amplifies the inflammatory response. Gene Immunity 3:123-135. (Pubitemid 38961122)
61. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, et al. (2001) The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 33:125-147. (Pubitemid 32703253)
62. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, et al. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advances glycation end products. J Immunol 174:7506-7515. (Pubitemid 40806253)
63. Cardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO reports 3:995-1001. (Pubitemid 35256475)
64. Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, et al. (2004) Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 76:994-1001. (Pubitemid 39462000)
65. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, et al. (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5:825-830. (Pubitemid 39199174)
66. Daemen MARC, van 't Veer C, Denecker G, Heemskerk VH, Wolfs TGAM, et al. (1999) Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 104:541-549.
67. Gujral JS, Bucci TJ, Farhood A, Jaescjke H (2001) Mechanisms of cell death during warm hepatic ischemia-reperfusion in rats: apoptosis or necrosis? Hepatology 33:397-405. (Pubitemid 32119028)
68. Sterner R, Vidali G, Allfrey VG (1979) Studies of acetylation and deacetylation in High Mobility Group proteins. J Biol Chem 254:11577-11583.
69. Elenkov I, Pelovsky P, Ugrinova I, Takahashi M, Pasheva E (2011) The DNA binding and bending activities of truncated tail-less HMGB1 protein are differentially affected by Lys-2 and Lys-81 residues and their acetylation. Int J Biol Sci 7:691-699.
70. Zhang X, Wheeler D, Tang Y, Guo L, Shapiro RA, et al. (2008) Calcium/calmodulin dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol 181:5015-5023.
71. Semino C, Angelini G, Poggi A, Rubartelli A (2005) NK/iDC interaction reults in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106:609-616. (Pubitemid 40981258)
72. Xu H, Su Z, Wu J, Yang M, Penninger JM, et al. (2010) The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the loppolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase γ pathway. J Immunol 184:1492-1498.
73. Board PG, Baker RT, Chelvanayagam G, Jermiin LS (1997) Zeta, a novel class of glutathione transferases in a range of species from plants to humans. Biochem J 328:929-935. (Pubitemid 28005795)
74. Board PG, Coggan M, Chelvanayagam G, Easteal S, Jermiin LS, et al. (2000) Identification, characterization, and crystal structure of the Omega class glutathione transferases. J Biol Chem 275:24798-24806. (Pubitemid 30626584)
75. Kodym R, Calkins P, Story M (1999) The cloning and characterization of a new stress response protein. A mammalian member of a family of θ class glutathione s-transferase-like proteins. J Biol Chem 274:5131-5137.
76. Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, et al. (2010) Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 31:804-811.
77. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376:167-170.
78. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, et al. (1999) Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-beta-deficient mice. Immunity 10:421-429. (Pubitemid 29205478)